Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,101-1,150 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__178_C8,15 | Lung | Primary cancer | 222 | Other | 64.4% | 0.89 | 0.30 |
| NSCLC_38242124__IMC__178_C8,16 | Lung | Primary cancer | 7,014 | Immune | 91.8% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__178_C8,17 | Lung | Primary cancer | 2,871 | Other | 93.7% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__178_C8,2 | Lung | Primary cancer | 4,815 | Tumor/Malignant | 85.4% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__178_C8,3 | Lung | Primary cancer | 745 | Tumor/Malignant | 35.6% | 0.87 | 0.24 |
| NSCLC_38242124__IMC__178_C8,4 | Lung | Primary cancer | 3,888 | Immune | 47.5% | 0.90 | 0.28 |
| NSCLC_38242124__IMC__178_C8,5 | Lung | Primary cancer | 2,405 | Tumor/Malignant | 33.1% | 0.55 | 0.81 |
| NSCLC_38242124__IMC__178_C8,6 | Lung | Primary cancer | 4,252 | Tumor/Malignant | 70.9% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__178_C8,8 | Lung | Primary cancer | 3,902 | Tumor/Malignant | 48.7% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__178_C8,9 | Lung | Primary cancer | 3,102 | Tumor/Malignant | 62.5% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__86_A1,1 | Lung | Primary cancer | 2,414 | Stromal | 33.0% | 0.78 | 0.55 |
| NSCLC_38242124__IMC__86_A1,10 | Lung | Primary cancer | 1,094 | Stromal | 36.4% | 0.70 | 0.67 |
| NSCLC_38242124__IMC__86_A1,11 | Lung | Primary cancer | 2,660 | Tumor/Malignant | 46.2% | 0.92 | 0.19 |
| NSCLC_38242124__IMC__86_A1,13 | Lung | Primary cancer | 4,008 | Tumor/Malignant | 50.5% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__86_A1,14 | Lung | Primary cancer | 3,589 | Stromal | 35.0% | 0.66 | 0.70 |
| NSCLC_38242124__IMC__86_A1,2 | Lung | Primary cancer | 3,803 | Tumor/Malignant | 26.4% | 0.86 | 0.50 |
| NSCLC_38242124__IMC__86_A1,5 | Lung | Primary cancer | 2,479 | Stromal | 31.7% | 0.54 | 0.81 |
| NSCLC_38242124__IMC__86_A1,6 | Lung | Primary cancer | 4,205 | Tumor/Malignant | 49.3% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__86_A1,7 | Lung | Primary cancer | 2,829 | Tumor/Malignant | 43.0% | 0.91 | 0.33 |
| NSCLC_38242124__IMC__86_A1,8 | Lung | Primary cancer | 844 | Stromal | 47.3% | 0.89 | 0.22 |
| NSCLC_38242124__IMC__86_A1,9 | Lung | Primary cancer | 4,113 | Tumor/Malignant | 81.7% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__86_A2,1 | Lung | Primary cancer | 4,130 | Immune | 65.1% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__86_A2,10 | Lung | Primary cancer | 2,069 | Stromal | 28.4% | 0.39 | 1.03 |
| NSCLC_38242124__IMC__86_A2,11 | Lung | Primary cancer | 4,785 | Tumor/Malignant | 33.9% | 0.89 | 0.32 |
| NSCLC_38242124__IMC__86_A2,12 | Lung | Primary cancer | 3,689 | Tumor/Malignant | 67.0% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__86_A2,13 | Lung | Primary cancer | 3,237 | Tumor/Malignant | 42.5% | 1.00 | 0.05 |
| NSCLC_38242124__IMC__86_A2,14 | Lung | Primary cancer | 4,439 | Tumor/Malignant | 77.3% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__86_A2,2 | Lung | Primary cancer | 488 | Tumor/Malignant | 57.0% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__86_A2,3 | Lung | Primary cancer | 3,769 | Tumor/Malignant | 44.8% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__86_A2,4 | Lung | Primary cancer | 2,367 | Stromal | 37.0% | 0.60 | 0.83 |
| NSCLC_38242124__IMC__86_A2,5 | Lung | Primary cancer | 2,045 | Stromal | 38.6% | 0.85 | 0.39 |
| NSCLC_38242124__IMC__86_A2,6 | Lung | Primary cancer | 2,533 | Stromal | 35.4% | 0.53 | 0.93 |
| NSCLC_38242124__IMC__86_A2,7 | Lung | Primary cancer | 2,781 | Tumor/Malignant | 41.0% | 0.93 | 0.26 |
| NSCLC_38242124__IMC__86_A2,8 | Lung | Primary cancer | 3,309 | Tumor/Malignant | 60.9% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__86_A2,9 | Lung | Primary cancer | 3,159 | Stromal | 24.6% | 0.67 | 0.69 |
| NSCLC_38242124__IMC__86_A3,10 | Lung | Primary cancer | 4,172 | Tumor/Malignant | 62.4% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__86_A3,11 | Lung | Primary cancer | 486 | Stromal | 33.3% | 0.60 | 0.78 |
| NSCLC_38242124__IMC__86_A3,12 | Lung | Primary cancer | 2,560 | Tumor/Malignant | 48.7% | 0.90 | 0.27 |
| NSCLC_38242124__IMC__86_A3,13 | Lung | Primary cancer | 3,849 | Tumor/Malignant | 93.8% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_A3,14 | Lung | Primary cancer | 1,921 | Tumor/Malignant | 26.3% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__86_A3,2 | Lung | Primary cancer | 964 | Stromal | 45.3% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__86_A3,3 | Lung | Primary cancer | 1,991 | Tumor/Malignant | 40.0% | 0.73 | 0.59 |
| NSCLC_38242124__IMC__86_A3,5 | Lung | Primary cancer | 2,886 | Tumor/Malignant | 69.3% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__86_A3,6 | Lung | Primary cancer | 1,225 | Tumor/Malignant | 38.8% | 0.77 | 0.51 |
| NSCLC_38242124__IMC__86_A3,8 | Lung | Primary cancer | 1,950 | Tumor/Malignant | 40.7% | 0.64 | 0.72 |
| NSCLC_38242124__IMC__86_A3,9 | Lung | Primary cancer | 1,438 | Stromal | 30.5% | 0.75 | 0.59 |
| NSCLC_38242124__IMC__86_A4,10 | Lung | Primary cancer | 3,091 | Tumor/Malignant | 62.3% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__86_A4,11 | Lung | Primary cancer | 4,264 | Tumor/Malignant | 57.5% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__86_A4,12 | Lung | Primary cancer | 1,518 | Stromal | 37.5% | 0.66 | 0.73 |
| NSCLC_38242124__IMC__86_A4,13 | Lung | Primary cancer | 3,702 | Tumor/Malignant | 67.7% | 0.97 | 0.10 |